

Ad hoc announcement pursuant to Art. 53 LR

Basel, 23 July 2026

Roche's strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

- **Group sales** were +6% at constant exchange rates (CER)¹, -2% when reported in CHF and +8% in USD², in the first six months, driven by high demand for innovative medicines and diagnostics.
- **Pharmaceuticals Division sales** were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas; Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers.
- **Diagnostics Division sales** were +3% at CER, -3% when reported in CHF and +6% in USD, driven by demand for immunodiagnostic and clinical chemistry products as well as pathology and molecular solutions.
- **Core operating profit** was +10% at CER, -1% when reported in CHF, driven by higher sales and other revenue; **IFRS operating profit** was -6% in CHF due to the appreciation of the Swiss franc.
- **Core earnings per share** were +9% at CER (-2% in CHF); **IFRS diluted earnings per share** were -8% in CHF due to the appreciation of the Swiss franc.
- **Highlights:**
 - US Priority Reviews for **giredestrant** in an early-stage breast cancer, **Enspryng** in thyroid eye disease, **Tecentriq** in colon cancer as well as **Gazyva/Gazyvaro** in idiopathic nephrotic syndrome and primary membranous nephropathy, two autoimmune diseases affecting the kidneys
 - US acceptance of a supplemental Biologics License Application for the **Lunsumio** and **Polivy** combination for blood cancer and **Gazyva/Gazyvaro** for systemic lupus erythematosus
 - Positive phase III data on **divarasib** in lung cancer; presentation of promising data on **fenebrutinib** in multiple sclerosis (phase III), **Gazyva/Gazyvaro** in three autoimmune diseases (phase III) and **enicepatide** (CT-388) and **petrelintide** in obesity (phase II)

- Launch of **Axelos 1**, a transformative next-generation sequencing platform based on the innovative SBX technology, enabling the fastest DNA sequencing at scale
- EU CE mark for two blood tests: **Elecsys pTau217** to detect Alzheimer's pathology and **Elecsys IGRA TB** to identify latent tuberculosis infection
- US approval for **Ventana PTEN (SP218) Rx Dx Assay**, the first companion diagnostic to assess the levels of a key protein in prostate cancer
- Global collaboration agreement with **Nurix Therapeutics** for the BTK degrader bexobrutideg across malignant haematology, immunology and neurology
- Agreement to acquire **PathAI** to transform AI-driven diagnostics
- Outlook for 2026 confirmed.

Outlook for 2026

Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs.

Key figures	CHF millions		% change		
	2026	2025	At CER ¹	In CHF	In USD
January–June					
Group sales	30,364	30,944	6	-2	8
Pharmaceuticals Division	23,629	23,985	6	-1	8
Diagnostics Division	6,735	6,959	3	-3	6
Core operating profit	11,856	12,010	10	-1	
Core EPS – diluted (CHF)	10.85	11.08	9	-2	
IFRS operating profit	9,671	10,330	6	-6	

Roche CEO Thomas Schinecker: “Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development.

We reported positive phase III data for **divarasib**, reinforcing its potential as a best-in-class therapy in advanced lung cancer. Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews: **giredestrant** in early-stage breast cancer, **Enspryng** in thyroid eye disease, **Tecentriq** in colon cancer and **Gazyva/Gazyvaro** in two autoimmune kidney diseases.

In Diagnostics, we reached major milestones with the launch of our transformative, highly cost-effective **Axelos 1** sequencing solution, alongside EU CE mark for key diagnostic tests, including the **Elecsys pTau217** blood test for Alzheimer’s pathology and the **Elecsys IGRA TB** blood test, which delivers automated, scalable latent tuberculosis screening to laboratories worldwide.

Backed by our robust pipeline, we are well-positioned for sustained future growth. We confirm our outlook.”

Group results

In the first six months of 2026, Roche **sales** were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates.

Core operating profit was +10% at CER (-1% in CHF) to CHF 11.9 billion, driven by higher sales and other revenue. **Core earnings per share** were +9% at CER (-2% in CHF).

IFRS operating profit was -6% in CHF to CHF 9.7 billion. **IFRS diluted earnings per share** were -8% in CHF. The IFRS results were impacted by the appreciation of the Swiss franc.

Sales in the **Pharmaceuticals Division** were +6% at CER, -1% when reported in CHF, to CHF 23.6 billion, with our medicines across disease areas continuing their strong growth.

The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 11.0 billion, an increase of 12% at CER, or 4% in CHF, compared to the first six months of 2025.

Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) were CHF 2.6 billion, a decrease of 8% at CER, or 15% in CHF, compared to the first six months of 2025.

In the **United States**, sales were +6% at CER, -3% when reported in CHF, due to continued growth of Xolair, Hemlibra, Polivy (blood cancer) and Tecentriq. This growth more than compensated for the lower sales of Perjeta (breast cancer) and Kadcyla (breast cancer) as well as the impact of biosimilar erosion on Actemra/RoActemra (rheumatoid arthritis).

Sales in **Europe** were +1% at CER, or -1% when reported in CHF, as demand for Ocrevus, Evrysdi (spinal muscular atrophy) and Phesgo more than offset the impact of lower sales of Actemra/RoActemra due to biosimilar competition and Perjeta because of the conversion of patients to Phesgo.

In **Japan**, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.

Sales in the **International** region were +10% at CER, or +4% when reported in CHF, led by Phesgo, Vabysmo, Hemlibra, Ocrevus and Polivy. In China, sales were -9% at CER, or -12% when reported in CHF, due to the base effect of a severe flu season in 2025 on Xofluza sales.

The **Diagnostics Division's** sales were +3% at CER, -3% when reported in CHF, to CHF 6.7 billion, driven by growth in demand for immunodiagnostic and clinical chemistry products as well as pathology and molecular solutions. This growth more than offset the impact of healthcare pricing reforms in China.

Sales in the **Europe, Middle East and Africa (EMEA)** region were +3% at CER, -1% when reported in CHF, driven by higher sales of immunodiagnostic products, the clinical chemistry portfolio and molecular solutions.

In **North America**, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas.

Sales in **Asia-Pacific** were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region.

In **Latin America**, sales were +10% at CER, or +5% when reported in CHF.

Pharmaceuticals: key developments

Compound	Milestone
Regulatory	
Gazyva/Gazyvaro Several autoimmune diseases	FDA grants Priority Review for Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy (pMN) - The Priority Review decision is based on results from the phase III MAJESTY study, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus. - If approved, Gazyva/Gazyvaro will be the first FDA-approved therapy for pMN, following global approvals in lupus nephritis and ongoing regulatory filings in systemic lupus erythematosus and idiopathic nephrotic syndrome. - pMN is a chronic autoimmune disease with no FDA- or EMA-approved therapies to date; when left untreated, up to 30% of patients progress to kidney failure over a period of 10 years.
Enspryng Thyroid eye disease	FDA grants Priority Review for Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) - The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED. - Enspryng has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED. - TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision-threatening complications if left untreated.
Lunsumio and Polivy Blood cancer	FDA accepts supplemental Biologics License Application for Lunsumio and Polivy combination for relapsed or refractory large B-cell lymphoma (LBCL) - Filing acceptance is based on data from the phase III SUNMO study, where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death. - People with relapsed or refractory LBCL represent a population with one of the highest unmet needs in lymphoma and require timely access to effective therapies. - If approved, this outpatient-ready regimen could enable access to care in the community setting, where most US patients receive treatment.

Tecentriq Colon cancer	FDA grants Priority Review for Tecentriq for a certain type of stage III colon cancer - Filing acceptance is based on data from the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone. - Nearly one in three patients with stage III colon cancer relapses within five years, highlighting a critical need for new adjuvant treatment options. - If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H colon cancer after surgery.
Giredestrant Breast cancer	FDA accepts New Drug Application for giredestrant in ER-positive early-stage breast cancer, the first and only oral selective oestrogen receptor degrader with positive phase III results in the curative setting - Filing acceptance, under Priority Review, is based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy. - Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years. - Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of ER-positive breast cancer cases are diagnosed at an early stage (I–III). - The FDA has set a Prescription Drug User Fee Act date of 30 November 2026.
Phase III, pivotal and other key read-outs	
Divarasib Lung cancer	Divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer - Phase III (Krucendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer. - Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed. - Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population.
Fenebrutinib Multiple sclerosis	Fenebrutinib significantly reduces relapses versus standard of care to approximately one every 17 years in relapsing multiple sclerosis (RMS) - Late-breaking phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in RMS. - Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide. - Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral medication for both RMS and primary progressive multiple sclerosis (PPMS).

Other	
Alzheimer's integrated portfolio presentation	Roche presents new data on Alzheimer's disease from across its integrated pharmaceuticals and diagnostics portfolio at AAIC • Five oral presentations in a featured research session highlighted trontinemab, including new long-term data from the phase Ib/IIa Brainshuttle AD study and the design of phase III PreventRON study in preclinical Alzheimer's disease. • New data on Roche's CE-marked Elecsys pTau217 blood test were presented on its use for the diagnosis of Alzheimer's disease in both primary and secondary care.
Nurix Therapeutics collaboration	Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology • Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies. • Collaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis). • Bexobrutideg utilises a novel approach to eliminate the Bruton's tyrosine kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors.
Obesity portfolio data presentation	Roche presents new data advancing its obesity portfolio at the American Diabetes Association's 2026 scientific sessions • Late-breaking phase II data highlight enicepatide's (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity. • Late-breaking data from the phase II ZUPREME-1 trial showcase petrelintide's efficacy, safety and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity. • A phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated in the coming months to develop a differentiated treatment option.
Oncology portfolio data presentation	Roche presents new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer • New data were presented from the lidERA study on giredestrant's potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages. • Primary results were presented from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease. • Overall, Roche highlighted data on nine approved and investigational medicines – including bispecific antibodies, antibody-drug conjugates and brain-permeable molecules – that target urgent needs in breast, blood, lung and other cancers.

Ophthalmology portfolio data presentation	Roche presents extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 • New real-world data confirm the potent retinal drying of Vabysmo in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME). • Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden. • Roche presented more than 45 abstracts at ARVO 2026, including 20 oral presentations across five retinal conditions.
--	---

Pharmaceuticals sales

Sales	CHF millions		As % of sales		% change	
January–June	2026	2025	2026	2025	At CER	In CHF
Pharmaceuticals Division	23,629	23,985	100.0	100.0	6	-1
United States	12,229	12,670	51.8	52.8	6	-3
Europe	4,520	4,566	19.1	19.0	1	-1
Japan	1,360	1,425	5.8	5.9	11	-5
International	5,520	5,324	23.3	22.3	10	4

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Top 20 best-selling pharmaceuticals	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus Multiple sclerosis	3,470	7	2,300	2	758	10	-	-	412	30
Hemlibra Haemophilia A	2,492	11	1,313	9	502	4	171	9	506	26
Vabysmo Eye diseases (nAMD, DME, RVO)	2,059	8	1,333	1	386	5	75	26	265	65
Tecentriq Cancer immunotherapy	1,704	6	815	9	410	-3	146	-2	333	17
Xolair ³ Chronic hives, food allergies	1,673	27	1,673	27	-	-	-	-	-	-
Perjeta ³ Breast cancer	1,389	-7	551	-11	238	-14	24	-23	576	0
Phesgo Breast cancer	1,318	18	318	0	425	9	88	15	487	47
Actemra/RoActemra ³ RA, COVID-19	1,074	-9	515	-9	238	-21	140	8	181	-3
Evrysdi Spinal muscular atrophy	968	17	323	15	335	17	39	-1	271	25
Kadcyla ³ Breast cancer	916	-6	310	-14	248	-4	39	2	319	3
Polivy Blood cancer	808	20	381	28	128	-18	98	16	201	47
Alecensa Lung cancer	795	6	261	4	126	-4	93	8	315	13
MabThera/Rituxan ³ Blood cancer, RA	609	5	402	14	62	-9	6	-11	139	-10
Activase/TNKase ³ Cardiac diseases	555	11	531	11	-	-	-	-	24	12
Gazyva/Gazyvaro ³ Blood cancer, lupus nephritis	489	7	240	4	117	-1	17	14	115	21
Herceptin ³ Breast and gastric cancer	462	-12	94	-14	136	-7	2	-36	230	-14

Avastin³ Various cancer types	414	-15	125	-12	35	37	36	-44	218	-13
Pulmozyme³ Cystic fibrosis	204	-8	145	-5	29	-11	-	26	30	-18
Columvi Blood cancer	196	70	91	28	53	116	-	-	52	173
Enspryng Acute inflammation of brain, spinal cord and optic nerves	195	22	50	20	23	20	79	18	43	37

DME: diabetic macular edema / nAMD: neovascular or 'wet' age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis

Diagnostics: key developments

Product	Milestone
cobas HDV test	Roche introduces cobas hepatitis D virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis - The new test enables clinicians to reliably diagnose HDV and monitor patients' treatment response. - Hepatitis D affects nearly 12 million people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types. - The cobas HDV test is the first high-throughput, fully automated HDV assay on the market, addressing the urgent need for a consistent, widely accessible solution and expanding access to critical testing just as new treatments for the disease become available.
Elecsys IGRA TB test	Roche receives CE mark for blood test to identify tuberculosis infection - The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress towards the World Health Organization's elimination targets. - Performed on Roche's industry-leading and widely available cobas immunoassay systems, the test enables laboratories to meet growing tuberculosis infection testing needs by reducing reliance on manual workflows through automation and digital solutions. - The new solution provides rapid, high-throughput and cost-effective tuberculosis testing, delivers reliable results in under 24 hours and cuts standard processing times in half to just 19 minutes per patient.
Axelios 1 sequencing platform	Roche announces the launch of Axelios 1, a transformative next-generation sequencing platform Axelios 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications.

	• Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours. • The Axelios 1 platform holds promise for research laboratories today, and potentially for a broad range of clinical settings in the future.
Ventana PTEN (SP218) RxDx Assay	Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer • The new Ventana PTEN (SP218) RxDx Assay fulfills an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with Truqap. • In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments. • The FDA approval reinforces Roche's leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes.
Liver Disease Panel	Roche launches the Liver Disease Panel, the first suite of certified algorithms to support chronic liver disease (CLD) management • Roche introduces the first comprehensive library of certified healthcare algorithms to support CLD management. • The Liver Disease Panel includes LiverPRO – a certified algorithm developed by the health tech company Evidio – requiring only age and routine blood markers for the timely detection of liver fibrosis. • With CLD affecting 1.5 billion people worldwide, the non-invasive panel solution covers care along the patient pathway from fibrosis risk identification to the surveillance of liver cancer.
Elecsys pTau217 test	Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys plasma phosphorylated-tau 217 (pTau217) • Elecsys pTau217 is the first blood test for Alzheimer's disease pathology with a single-assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world. • While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw. • Diagnosing dementia currently takes 3.5 years on average, and an estimated 75% of people living with dementia remain undiagnosed. Elecsys pTau217 offers a simple blood test to aid in earlier, more accessible Alzheimer's disease diagnosis for millions of patients around the world.
PathAI agreement	Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics • PathAI's best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiency.

	- Combining Roche's strong position in companion diagnostics and PathAI's advanced AI platform helps accelerate clinical therapy development, foster the discovery of new biomarkers and create novel diagnostic tools. - These integrated capabilities will accelerate the shift from broad intervention towards personalised healthcare for patients.
--	--

Diagnostics sales

Sales	CHF millions		As % of sales		% change	
January-June	2026	2025	2026	2025	At CER	In CHF
Diagnostics Division	6,735	6,959	100.0	100.0	3	-3
Customer areas						
Core Lab	3,756	3,839	55.8	55.2	4	-2
Molecular Lab	1,196	1,250	17.7	18.0	3	-4
Near Patient Care	909	1,018	13.5	14.6	-5	-11
Pathology Lab	874	852	13.0	12.2	11	3
Regions						
Europe, Middle East, Africa	2,466	2,485	36.6	35.7	3	-1
North America	2,211	2,235	32.8	32.1	8	-1
Asia-Pacific	1,522	1,729	22.6	24.9	-5	-12
Latin America	536	510	8.0	7.3	10	5

Roche's Half-Year Results 2026 Webinar

There will be a live webinar for investors and analysts today, Thursday, 23 July at 14:00 CEST. To access the webinar, please click [here](#).

Additional information

Half-Year 2026 Presentation: <http://www.roche.com/irp260723-a.pdf>

Half-Year 2026 Presentation with appendix: <http://www.roche.com/irp260723.pdf>

Half-Year Report 2026: <http://www.roche.com/hy26e.pdf>

Group Pharmaceuticals pipeline: <http://www.roche.com/pharmahy26.pdf>

Group Diagnostics pipeline: <http://www.roche.com/diahy26.pdf>

About Roche

Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025.

[2] USD (US dollars). The percentage changes for selected sales figures in US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies.

[3] Products launched before 2015.

Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Roche Investor Relations

Dr Bruno Eschli

Phone: +41 61 687 52 84

E-mail: bruno.eschli@roche.com

Dr Sabine Borngräber

Phone: +41 61 688 80 27

E-mail: sabine.borngraeber@roche.com

Dr Birgit Masjost

Phone: +41 61 688 48 14

E-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 32 17

E-mail: kalm.loren@gene.com

Appendix: Tables

1.	Sales January to June 2026 and 2025.....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2026 vs. YTD June 2025	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth.....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan.....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the six months ended 30 June 2026	11
10.	Roche Group core results reconciliation – Half Year 2026	12
11.	Divisional core results reconciliation – Half Year 2026	13
12.	Roche Group consolidated balance sheet.....	14
13.	Roche Group consolidated statement of cash flows.....	15

1. Sales January to June 2026 and 2025

CHF millions	Six months ended 30 June		% change	
	2026	2025	At CER	In CHF
Pharmaceuticals Division	23,629	23,985	6	-1
United States	12,229	12,670	6	-3
Europe	4,520	4,566	1	-1
Japan	1,360	1,425	11	-5
International	5,520	5,324	10	4
Diagnostics Division	6,735	6,959	3	-3
Roche Group	30,364	30,944	6	-2

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Pharmaceuticals Division	12,036	11	11,570	7	12,114	9	11,469	7	12,160	6
United States	6,446	13	6,128	5	6,557	9	5,693	5	6,536	7
Europe	2,246	5	2,252	5	2,346	7	2,234	-1	2,286	3
Japan	754	7	714	6	743	4	649	14	711	9
International	2,590	11	2,476	11	2,468	16	2,893	16	2,627	4
Diagnostics Division	3,468	0	3,348	2	3,540	6	3,253	3	3,482	4
Roche Group	15,504	8	14,918	6	15,654	8	14,722	6	15,642	5

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2026 vs. YTD June 2025

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,470	7	2,300	2	758	10	-	-	412	30
Hemlibra	2,492	11	1,313	9	502	4	171	9	506	26
Vabysmo	2,059	8	1,333	1	386	5	75	26	265	65
Tecentriq	1,704	6	815	9	410	-3	146	-2	333	17
Xolair	1,673	27	1,673	27	-	-	-	-	-	-
Perjeta	1,389	-7	551	-11	238	-14	24	-23	576	0
Phesgo	1,318	18	318	0	425	9	88	15	487	47
Actemra/RoActemra	1,074	-9	515	-9	238	-21	140	8	181	-3
Evrysdi	968	17	323	15	335	17	39	-1	271	25
Kadcyla	916	-6	310	-14	248	-4	39	2	319	3
Polivy	808	20	381	28	128	-18	98	16	201	47
Alecensa	795	6	261	4	126	-4	93	8	315	13
MabThera/Rituxan	609	5	402	14	62	-9	6	-11	139	-10
Activase/TNKase	555	11	531	11	-	-	-	-	24	12
Gazyva	489	7	240	4	117	-1	17	14	115	21
Herceptin	462	-12	94	-14	136	-7	2	-36	230	-14
Avastin	414	-15	125	-12	35	37	36	-44	218	-13
Pulmozyme	204	-8	145	-5	29	-11	-	26	30	-18
Columvi	196	70	91	28	53	116	-	-	52	173
Enspryng	195	22	50	20	23	20	79	18	43	37
Elevidys	180	62	-	-	2	-	22	-	156	39
Itovebi	104	212	81	164	7	*	-	-	16	*
Lunsumio	100	130	65	136	9	-17	21	348	5	500

Xofluza	74	-58	22	37	2	24	-	-	50	-69
Rozlytrek	66	-10	16	-33	12	10	2	-18	36	1
PiaSky	30	62	-	-	7	140	22	47	1	-7
Cotellic	23	2	11	7	5	-9	-	-	7	2
Luxturna	22	-32	22	-32	-	-	-	-	-	-
Susvimo	9	109	9	109	-	-	-	-	-	-
Pharma other	1,231	-8	232	-22	227	0	240	26	532	-15
Pharma total sales	23,629	6	12,229	6	4,520	1	1,360	11	5,520	10

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	1,728	10	1,684	6	1,820	16	1,692	6	1,778	7
Hemlibra	1,256	22	1,105	4	1,228	8	1,190	13	1,302	9
Vabysmo	1,049	19	996	4	1,039	7	1,024	13	1,035	3
Tecentriq	863	-1	883	4	950	8	811	4	893	9
Xolair	800	41	781	34	849	26	708	26	965	28
Perjeta	773	-14	703	-14	652	-13	672	-11	717	-3
Phesgo	604	57	630	51	614	34	686	27	632	9
Actemra/RoActemra	660	8	614	-2	577	-10	534	-4	540	-14
Evrysdi	449	-1	424	10	464	26	464	19	504	16
Kadcyla	531	12	494	7	494	6	439	-4	477	-7
Polivy	372	51	371	30	369	31	407	26	401	14
Alecensa	405	6	388	8	372	1	401	12	394	1
MabThera/Rituxan	332	1	303	3	318	-3	292	10	317	0
Activase/TNKase	253	-7	283	1	274	-2	255	-2	300	24
Gazyva	241	12	238	13	258	15	247	10	242	4
Herceptin	268	-23	257	-15	211	-29	234	-12	228	-12
Avastin	248	-19	241	-11	210	-21	224	-9	190	-20
Pulmozyme	116	13	122	26	118	1	89	-18	115	3
Columvi	63	58	79	71	86	64	95	77	101	64
Enspryng	94	27	92	25	95	17	96	31	99	15

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	1,215	8	1,151	1	1,261	17	1,117	3	1,183	2
Hemlibra	714	21	617	-1	724	6	613	15	700	4
Vabysmo	732	10	689	-4	718	-1	652	4	681	-2
Tecentriq	408	-4	403	2	418	4	378	6	437	12
Xolair	800	41	781	34	849	26	708	26	965	28
Perjeta	335	4	291	-6	300	4	263	-12	288	-10
Phesgo	169	40	175	29	185	22	159	2	159	-2
Actemra/RoActemra	325	11	307	-6	280	-19	248	-3	267	-13
Evrysdi	149	10	159	18	144	0	160	15	163	15
Kadcyla	195	9	181	2	191	10	156	-11	154	-17
Polivy	171	34	170	18	191	32	171	26	210	29
Alecensa	146	19	144	15	145	4	105	-7	156	13
MabThera/Rituxan	206	2	188	5	219	5	183	16	219	13
Activase/TNKase	242	-5	270	1	259	-2	244	-2	287	24
Gazyva	122	14	123	14	143	20	115	1	125	8
Herceptin	61	-8	54	-6	50	-14	44	-16	50	-13
Avastin	76	-18	69	-16	74	-14	59	-15	66	-8
Pulmozyme	83	22	87	30	89	8	58	-21	87	11
Columvi	41	88	47	90	53	70	43	35	48	23
Enspryng	25	20	25	9	26	1	22	20	28	20

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	362	14	354	12	391	14	363	9	395	11
Hemlibra	246	7	247	14	262	12	252	5	250	3
Vabysmo	181	25	178	9	185	13	190	0	196	10
Tecentriq	214	1	216	0	228	7	202	-6	208	-1
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	138	-15	136	-14	134	-7	119	-15	119	-12
Phesgo	202	13	201	9	210	9	206	7	219	10
Actemra/RoActemra	156	-7	142	-1	138	-7	124	-16	114	-27
Evrysdi	147	3	158	7	166	21	159	13	176	21
Kadcyla	131	-5	130	-5	136	0	123	-6	125	-3
Polivy	66	119	68	21	62	26	63	-32	65	1
Alecensa	65	-7	64	-10	65	-3	63	-5	63	-2
MabThera/Rituxan	35	-6	34	13	36	-13	31	-8	31	-9
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	61	4	62	1	62	5	57	-2	60	-1
Herceptin	73	-2	73	2	68	-9	69	-7	67	-6
Avastin	12	-46	28	47	16	-22	14	3	21	76
Pulmozyme	16	-16	15	-3	16	-9	15	-14	14	-7
Columvi	13	70	18	51	19	65	21	84	32	142
Enspryng	9	36	11	37	10	36	11	20	12	21

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	101	12	92	11	102	5	81	18	90	3
Vabysmo	38	28	35	17	41	15	37	39	38	16
Tecentriq	93	-2	88	-1	87	-6	69	0	77	-4
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	19	-35	17	-27	15	-31	12	-19	12	-26
Phesgo	50	59	49	41	49	11	42	23	46	8
Actemra/RoActemra	81	6	78	4	80	6	66	9	74	7
Evrysdi	26	9	22	7	22	-9	18	4	21	-5
Kadcyla	24	0	23	-2	23	-7	19	6	20	-1
Polivy	55	14	54	14	54	5	46	24	52	10
Alecensa	51	-1	51	13	53	7	43	4	50	12
MabThera/Rituxan	4	-12	4	-3	3	-11	3	-6	3	-16
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	9	3	8	22	10	37	9	28	8	0
Herceptin	2	-46	2	-30	1	-33	1	-24	1	-47
Avastin	40	-21	35	-19	34	-21	21	-29	15	-56
Pulmozyme	-	-11	-	13	1	-21	-	43	-	14
Columvi	-	-	-	-	-	-	-	-	-	-
Enspryng	41	24	42	22	44	20	35	13	44	22

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025	Q2 2026	% change vs. Q2 2025
Ocrevus	151	23	179	35	168	11	212	24	200	37
Hemlibra	195	60	149	9	140	18	244	14	262	39
Vabysmo	98	130	94	111	95	118	145	126	120	24
Tecentriq	148	7	176	17	217	25	162	14	171	20
Xolair	-	-	-	-	-	-	-	-	-	-
Perjeta	281	-27	259	-21	203	-30	278	-9	298	10
Phesgo	183	230	205	213	170	122	279	78	208	19
Actemra/RoActemra	98	25	87	7	79	6	96	5	85	-10
Evrysdi	127	-15	85	4	132	116	127	40	144	14
Kadcyla	181	33	160	28	144	9	141	5	178	1
Polivy	80	94	79	105	62	67	127	120	74	-7
Alecensa	143	2	129	8	109	-3	190	39	125	-13
MabThera/Rituxan	87	2	77	-5	60	-22	75	6	64	-24
Activase/TNKase	11	-37	13	18	15	-4	11	-4	13	29
Gazyva	49	18	45	24	43	8	66	45	49	-1
Herceptin	132	-34	128	-25	92	-42	120	-14	110	-14
Avastin	120	-15	109	-13	86	-26	130	-1	88	-26
Pulmozyme	17	7	20	34	12	-19	16	-12	14	-24
Columvi	9	-16	14	48	14	45	31	204	21	135
Enspryng	19	40	14	60	15	32	28	93	15	-11

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

9. Roche Group consolidated income statement for the six months ended 30 June 2026

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	23,629	6,735	-	30,364
Other revenue	965	123	-	1,088
Cost of sales	(4,355)	(3,626)	-	(7,981)
Research and development	(6,336)	(901)	-	(7,237)
Selling, general and administration	(3,181)	(1,481)	(2,131)	(6,793)
Other operating income and expense	116	20	94	230
Operating profit	10,838	870	(2,037)	9,671
Financing costs				(642)
Other financial income (expense)				(56)
Profit before taxes				8,973
Income taxes				(1,648)
Net income				7,325
Attributable to				
- Roche shareholders				6,871
- Non-controlling interests				454
Earnings per share and non-voting equity security				
Basic (CHF)				8.63
Diluted (CHF)				8.52

10. Roche Group core results reconciliation – Half Year 2026

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	30,364	-	-	-	-	-	-	-	-	30,364
Other revenue	1,088	-	-	-	-	-	-	-	-	1,088
Cost of sales	(7,981)	130	178	-	-	-	-	-	-	(7,673)
Research and development	(7,237)	216	211	1,045	-	-	-	-	-	(5,765)
Selling, general and administration	(6,793)	421	2	-	-	-	-	-	-	(6,370)
Other operating income and expense	230	(2)	-	-	(18)	2	-	-	-	212
Operating profit	9,671	765	391	1,045	(18)	2	-	-	-	11,856
Financing costs	(642)	-	-	-	7	4	-	-	-	(631)
Other financial income (expense)	(56)	-	-	-	-	-	-	-	-	(56)
Profit before taxes	8,973	765	391	1,045	(11)	6	-	-	-	11,169
Income taxes	(1,648)	(155)	(75)	(96)	3	(1)	-	-	19	(1,953)
Net income	7,325	610	316	949	(8)	5	-	-	19	9,216
Attributable to										
- Roche shareholders	6,871	598	316	949	(8)	5	-	-	19	8,750
- Non-controlling interests	454	12	-	-	-	-	-	-	-	466
EPS - diluted (CHF)	8.52	0.74	0.39	1.18	(0.01)	0.01	-	-	0.02	10.85

11. Divisional core results reconciliation – Half Year 2026

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	23,629	-	-	-	-	-	-	23,629
Other revenue	965	-	-	-	-	-	-	965
Cost of sales	(4,355)	14	110	-	-	-	-	(4,231)
Research and development	(6,336)	185	211	1,045	-	-	-	(4,895)
Selling, general and administration	(3,181)	150	-	-	-	-	-	(3,031)
Other operating income and expense	116	(3)	-	-	(23)	5	-	95
Operating profit	10,838	346	321	1,045	(23)	5	-	12,532
Diagnostics								
Sales	6,735	-	-	-	-	-	-	6,735
Other revenue	123	-	-	-	-	-	-	123
Cost of sales	(3,626)	116	68	-	-	-	-	(3,442)
Research and development	(901)	31	-	-	-	-	-	(870)
Selling, general and administration	(1,481)	91	2	-	-	-	-	(1,388)
Other operating income and expense	20	1	-	-	1	-	-	22
Operating profit	870	239	70	-	1	-	-	1,180
Corporate								
Selling, general and administration	(2,131)	180	-	-	-	-	-	(1,951)
Other operating income and expense	94	-	-	-	4	(3)	-	95
Operating profit	(2,037)	180	-	-	4	(3)	-	(1,856)

12. Roche Group consolidated balance sheet

in millions of CHF	30 June 2026	31 December 2025	31 December 2024
Non-current assets			
Property, plant and equipment	22,457	21,949	22,557
Right-of-use assets	952	985	1,183
Goodwill	7,769	7,492	7,876
Intangible assets	19,320	19,321	17,303
Deferred tax assets	8,721	8,411	8,569
Defined benefit plan assets	1,506	1,791	2,256
Other non-current assets	2,039	2,025	2,021
Total non-current assets	62,764	61,974	61,765
Current assets			
Inventories	8,094	7,479	7,606
Accounts receivable	12,915	11,506	11,297
Current income tax assets	428	393	415
Other current assets	4,266	3,875	3,401
Marketable securities	4,286	9,894	10,342
Cash and cash equivalents	5,448	5,582	6,975
Total current assets	35,437	38,729	40,036
Total assets	98,201	100,703	101,801
Non-current liabilities			
Long-term debt	(25,222)	(27,430)	(30,722)
Net deferred tax liabilities	(824)	(884)	(832)
Defined benefit plan liabilities	(3,904)	(3,950)	(4,381)
Provisions	(1,157)	(1,055)	(1,079)
Other non-current liabilities	(1,531)	(1,503)	(1,603)
Total non-current liabilities	(32,638)	(34,822)	(38,617)
Current liabilities			
Short-term debt	(6,583)	(4,206)	(3,932)
Current income tax liabilities	(3,231)	(2,867)	(2,923)
Provisions	(1,630)	(1,743)	(1,726)
Accounts payable	(5,542)	(5,779)	(4,894)
Other current liabilities	(11,861)	(13,406)	(13,548)
Total current liabilities	(28,847)	(28,001)	(27,023)
Total liabilities	(61,485)	(62,823)	(65,640)
Total net assets	36,716	37,880	36,161
Equity			
Capital and reserves attributable to Roche shareholders	32,693	33,802	31,767
Equity attributable to non-controlling interests	4,023	4,078	4,394
Total equity	36,716	37,880	36,161

13. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2026	HY 2025
Cash flows from operating activities		
Cash generated from operations	13,739	13,791
(Increase) decrease in net working capital	(3,671)	(3,470)
Payments made for defined benefit plans	(331)	(326)
Utilisation of provisions	(529)	(658)
Other operating cash flows	0	0
Cash flows from operating activities, before income taxes paid	9,208	9,337
Income taxes paid	(1,573)	(2,237)
Total cash flows from operating activities	7,635	7,100
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,570)	(1,680)
Purchase of intangible assets	(1,301)	(1,476)
Disposal of property, plant and equipment	20	73
Disposal of intangible assets	0	2
Disposal of products	5	0
Business combinations and asset acquisitions	(402)	(895)
Divestment of subsidiaries	0	6
Interest and dividends received	73	88
Sales of marketable securities	262	123
Purchases of marketable securities	(166)	(61)
Sales (purchases) of money market instruments and time accounts over three months, net	5,465	5,665
Other investing cash flows	33	(12)
Total cash flows from investing activities	2,419	1,833
Cash flows from financing activities		
Proceeds from issue of bonds and notes	0	0
Redemption and repurchase of bonds and notes	(1,715)	(2,479)
Increase (decrease) in commercial paper	1,553	3,453
Increase (decrease) in other debt	(65)	292
Hedging and collateral arrangements	(284)	(156)
Interest paid	(538)	(588)
Principal portion of lease liabilities paid	(169)	(199)
Dividends paid	(8,273)	(7,943)
Reduction of the nominal value of bearer shares paid to Roche shareholders	(107)	-
Equity-settled equity compensation plans, net of transactions in own equity	(583)	(504)
Other financing cash flows	0	1
Total cash flows from financing activities	(10,181)	(8,123)
Net effect of currency translation on cash and cash equivalents	(7)	(231)
Increase (decrease) in cash and cash equivalents	(134)	579
Cash and cash equivalents at beginning of period	5,582	6,975
Cash and cash equivalents at end of period	5,448	7,554